Modality
mAb
MOA
C5i
Target
CD20
Pathway
Apoptosis
MSMyelofibrosis
Development Pipeline
Preclinical
~May 2015
→ ~Aug 2016
Phase 1
~Nov 2016
→ ~Feb 2018
Phase 2
~May 2018
→ ~Aug 2019
Phase 3
~Nov 2019
→ ~Feb 2021
NDA/BLA
May 2021
→ Dec 2031
NDA/BLACurrent
NCT03822446
1,997 pts·Myelofibrosis
2021-05→2028-06·Not yet recruiting
NCT05803139
2,401 pts·MS
2022-12→2031-12·Terminated
4,398 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (2)
2028-06-062.2y awayPh3 Readout· Myelofibrosis
2031-12-145.7y awayPh3 Readout· MS
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
NDA/BLA
Not yet…
NDA/BLA
Termina…
Catalysts
Ph3 Readout
2028-06-06 · 2.2y away
Myelofibrosis
Ph3 Readout
2031-12-14 · 5.7y away
MS
TerminatedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03822446 | NDA/BLA | Myelofibrosis | Not yet recr... | 1997 | EDSS |
| NCT05803139 | NDA/BLA | MS | Terminated | 2401 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-8637 | Johnson & Johnson | NDA/BLA | CD20 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| ARG-3265 | Argenx | Phase 1/2 | CD20 | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| CRS-6525 | CRISPR Therapeutics | Phase 2 | CD20 | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| AKR-4818 | Akero | Approved | CD20 | |
| Peminaritide | iTeos | NDA/BLA | CD20 |